Consistent with this result, the PTEN null glioblastoma cell line U-87MG and the prostate cancer cell line PC3 were found to be sensitive to Rapamycin in vitro (Di Nicolantonio et al., 2010), and when grown as xenografts to the dual PI3K/mTOR inhibitor BEZ235 (Maira et al., 2008) and the ATP-competitive mTOR inhibitor WYE-354 (Yu et al., 2009). Here, PTEN is linked to prostate cancer.